Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.87 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.87 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | NMT2 | O60551 | 2/20 | 0.35 |
| ▸ | NMT1 | P30419 | 2/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667923 | 1.00 | ITGB3 (0.87) | ITGB3ITGA2BMMP1MMP2MMP3 | |
| SCHEMBL14273418 | 0.93 | ITGB3 (0.76) | ITGB3ITGA2BMMP1MMP2MMP3 | |
| SCHEMBL6794771 | 0.93 | ITGB3 (0.79) | ITGB3ITGA2BMMP1MMP2MMP3 | |
| SCHEMBL6798763 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 | |
| SCHEMBL6800093 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 | |
| SCHEMBL6796377 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 | |
| SCHEMBL6800101 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 | |
| SCHEMBL6799933 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 | |
| SCHEMBL3673630 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 | |
| SCHEMBL6798767 | 0.93 | ITGB3 (1.00) | ITGB3ITGA2BF2RKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | AVENTIS PHARMACEUTICALS INC. | 2002-01-03 | — | — | US | claimed |
| EP-0812205-B1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 2001-03-14 | — | — | EP | claimed |
| EP-0812205-A4 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 1999-03-31 | — | — | EP | claimed |
| EP-0812205-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-12-17 | — | — | EP | claimed |
| WO-1995010295-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-20 | — | — | WO | claimed |
| US-6797700-B2 | ANTICOAGULANTS | AVENTIS PHARMACEUTICALS, INC. | 2004-09-28 | — | — | US | disclosed |
| US-6753409-B1 | FOR TREATMENT OF MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERIAL DISEASE AND DISSEMINATED INTRAVASCULAR COAGULATION | AVENTIS PHARMACEUTICALS INC. | 2004-06-22 | — | — | US | disclosed |
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | AVENTIS PHARMACEUTICALS INC. | 2002-01-03 | — | — | US | disclosed |
| EP-0929572-A4 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | AVENTIS PHARM PROD INC (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6274705-B1 | INHIBIT PLATELET AGGREGATION AND THROMBUS FORMATION, USEFUL IN PREVENTION AND TREATMENT OF THROMBOSIS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-14 | — | — | US | disclosed |
| EP-0812205-B1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6153588-A | USEFUL IN PROPHYLAXIS AND THREAPY OF THROMBOSIS ASSOCIATED WITH DISEASE STATES SUCH AS MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERIAL DISEASE AND DISSEMINATED INTRAVASCULAR COAGULATION | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0929572-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0812205-A4 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1998017678-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| EP-0812205-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-12-17 | — | — | EP | disclosed |
| WO-1995010295-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | PLAT, SELP, PIGS | ITGB3 280/4885ITGA2B 355/4885MMP1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.